Skip to content

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00545181
Enrollment
55
Registered
2007-10-17
Start date
2007-09-30
Completion date
2009-07-31
Last updated
2010-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Vaginosis

Keywords

bacterial vaginosis, vaginal acidifying gel, recurrence

Brief summary

Bacterial vaginosis (BV) is a common, complex clinical syndrome characterized by alterations in the normal vaginal flora. Bacterial vaginosis has been associated with a variety of adverse health outcomes including endometritis; post-abortion endometritis; nongonococcal, nonchlamydial pelvic inflammatory disease; and an increased risk of acquiring and transmitting HIV infection. In pregnancy, BV is associated with premature rupture of the membranes, chorioamnionitis, amniotic fluid infection, preterm labor, preterm birth, and postpartum endometritis. Several studies have documented increased postpartum complications in the newborn and infants. The etiology of BV is poorly understood but recurrence is quite common despite treatment. Documented recurrence rate of up to 30% within three months are reported. Small studies have shown that adding vaginal acidifying gel to standard antibiotic regimens may reduce recurrence rates of BV. We plan an RCT comparing standard antibiotic therapy to antibiotics plus vaginal acidifying gel. Our hypothesis is that the addition of an acidifying gel will decrease the chance of recurrence of BV within 3 months.

Detailed description

Women with recurrent BV will be randomly assigned to standard care of metronidazole vs metronidazole plus vaginal acidifying gel. Symptoms and presence of BV will be measured at followup.

Interventions

DRUGVaginal acidifying gel (RepHresh)

placement of vaginal acidifying gel into vagina to restore normal vaginal pH.

DRUGMetronidazole control

oral metronidazole therapy alone

Sponsors

Indiana University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. All women of between 18-50 years of age. 2. Confirmed current diagnosis of BV using Amsel's criteria. 3. Women with at least total 2 confirmed episodes of BV including most recent episode (by Amsel's criteria) within a six month period or at least total three or more in the past twelve months

Exclusion criteria

1. Patient who received antibiotic therapy within the past two weeks. 2. Patients who had co-existing gonorrhea or Chlamydia infection 3. Any contraindications or sensitivity to taking the vaginal gel. 4. Allergy to metronidazole 5. Alcoholics or those unable to abstain from alcohol consumption. 6. Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Recurrent Bacterial Vaginosis3 monthsRecurrence by either Amsel's or Nugent's criteria. Amsel's criteria are the presence of 3 of 4 of following: 1. homogenous gray-white vaginal discharge, 2. elevated vaginal pH \>4.7, 3. presence of at least 20% of vaginal epithelial cells being clue cells on wet prep microscopy, and 4. positive amine odor test on addition of 10% KOH. Nugent's criteria is based on microscopy and bacterial scoring of lactobaccilus, gardnerella, and curved gram-variable rods. A score of at least 7 is indicative of bacterial vaginosis.

Countries

United States

Participant flow

Participants by arm

ArmCount
Metronidazole + Acidifying Gel (RepHresh)
Receive metronidazole plus vaginal acidifying gel
29
Metronidazole Alone
Metronidazole antibiotic therapy alone
25
Total54

Baseline characteristics

CharacteristicMetronidazole AloneMetronidazole + Acidifying Gel (RepHresh)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
25 Participants29 Participants54 Participants
Age Continuous32.4 years
STANDARD_DEVIATION 6.9
29.8 years
STANDARD_DEVIATION 5.8
31.0 years
STANDARD_DEVIATION 6.4
Region of Enrollment
United States
25 participants29 participants54 participants
Sex: Female, Male
Female
25 Participants29 Participants54 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 290 / 25
serious
Total, serious adverse events
0 / 290 / 25

Outcome results

Primary

Recurrent Bacterial Vaginosis

Recurrence by either Amsel's or Nugent's criteria. Amsel's criteria are the presence of 3 of 4 of following: 1. homogenous gray-white vaginal discharge, 2. elevated vaginal pH \>4.7, 3. presence of at least 20% of vaginal epithelial cells being clue cells on wet prep microscopy, and 4. positive amine odor test on addition of 10% KOH. Nugent's criteria is based on microscopy and bacterial scoring of lactobaccilus, gardnerella, and curved gram-variable rods. A score of at least 7 is indicative of bacterial vaginosis.

Time frame: 3 months

ArmMeasureValue (NUMBER)
Metronidazole + Acidifying Gel (RepHresh)Recurrent Bacterial Vaginosis7 Participants
Metronidazole AloneRecurrent Bacterial Vaginosis7 Participants
p-value: 0.75Chi-squared, Corrected

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026